{"id":797,"date":"2026-06-22T15:22:34","date_gmt":"2026-06-22T13:22:34","guid":{"rendered":"https:\/\/infoimasd.com\/?p=797"},"modified":"2026-06-22T15:22:35","modified_gmt":"2026-06-22T13:22:35","slug":"ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela","status":"publish","type":"post","link":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/","title":{"rendered":"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA"},"content":{"rendered":"\n<p class=\"has-medium-font-size wp-block-paragraph\">Se abre una <strong>v\u00eda de esperanza en la lucha contra la Esclerosis Lateral Amiotr\u00f3fica.<\/strong> Una enfermedad que afecta a unas 4.000 personas en Espa\u00f1a con unos 900 nuevos casos diagnosticados cada a\u00f1o. <a href=\"https:\/\/infoimasd.com\/index.php\/2026\/06\/19\/la-investigacion-de-molefy-pharma-que-da-esperanza-frente-a-la-ela\/\" type=\"post\" id=\"758\">La v\u00eda de investigaci\u00f3n de Molefy Pharma y del CSIC est\u00e1 generando gran expectaci\u00f3n ahora que han comenzado los ensayos cl\u00ednicos.<\/a> La alteraci\u00f3n de la prote\u00edna TDP-43 que aparece en el 97% de los pacientes con ELA juega un papel determinante en el deterioro  e incluso la muerte de las neuronas motoras. La disfunci\u00f3n de esta prote\u00edna da lugar a los s\u00edntomas de la ELA. <a href=\"https:\/\/molefypharma.com\/es\/home-es\/\" type=\"link\" id=\"https:\/\/molefypharma.com\/es\/home-es\/\">Molefy Pharma<\/a>, con las investigadoras Carmen Gil y Ana Mart\u00ednez, trabaja con la mol\u00e9cula AP-2 que podr\u00eda curar la ELA al <strong>devolver a la prote\u00edna TDP-43 a su funci\u00f3n normal<\/strong> preservando as\u00ed las neuronas motoras. <\/p>\n\n\n\n<p class=\"has-medium-font-size wp-block-paragraph\">Los ensayos precl\u00ednicos fueron un \u00e9xito y <strong>ya ha comenzado la fase 1 cl\u00ednica con pruebas en voluntarios sanos. <\/strong>Estas primeras pruebas tienen como objetivo comprobar que el compuesto no produce efectos adversos. Est\u00e1 previsto que en 2027 comiencen las pruebas en pacientes con ELA. Una fase que determinar\u00e1 si el compuesto act\u00faa en el cerebro y en qu\u00e9 condiciones. Es el <strong>inicio de un largo camino que requerir\u00e1 mucho trabajo de investigaci\u00f3n, mucho tiempo (cinco a\u00f1os al menos) y mucha financiaci\u00f3n.<\/strong> Quiz\u00e1 podamos ver resultados en el pr\u00f3ximo lustro con un compuesto que podr\u00eda ralentizar el avance de la Esclerosis Lateral Amiotr\u00f3fica o incluso curarla. <strong>Aqu\u00ed puedes ver nuestro reportaje con entrevistas a las investigadoras del CSIC y cofundadoras de Molefy Pharma, Ana Mart\u00ednez y Carmen Gil:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA\" width=\"500\" height=\"281\" data-src=\"https:\/\/www.youtube.com\/embed\/jTxuQqTOq8s?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" data-load-mode=\"0\"><\/iframe>\n<\/div><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Se abre una v\u00eda de esperanza en la lucha contra la Esclerosis Lateral Amiotr\u00f3fica. Una enfermedad que afecta a unas 4.000 personas en Espa\u00f1a con unos 900 nuevos casos diagnosticados&hellip;<\/p>\n","protected":false},"author":1,"featured_media":798,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[11,17],"tags":[219,179,206,208,221,8,204,220],"class_list":["post-797","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investigacion","category-reportajes","tag-ap-2","tag-csic","tag-ela","tag-esclerosis-lateral-amiotrofica","tag-fase-clinica","tag-investigacion","tag-molefy-pharma","tag-tdp-43"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA - INFO I+D<\/title>\n<meta name=\"description\" content=\"La mol\u00e9cula AP-2 podr\u00eda curar la ELA. Este hallazgo es fruto de la investigaci\u00f3n del CSIC y de Molefy Pharma en relaci\u00f3n a la prote\u00edna TDP-43\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA - INFO I+D\" \/>\n<meta property=\"og:description\" content=\"La mol\u00e9cula AP-2 podr\u00eda curar la ELA. Este hallazgo es fruto de la investigaci\u00f3n del CSIC y de Molefy Pharma en relaci\u00f3n a la prote\u00edna TDP-43\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/\" \/>\n<meta property=\"og:site_name\" content=\"INFO I+D\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-22T13:22:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-22T13:22:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/06\/Portada-Wordpress-Molefy.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1421\" \/>\n\t<meta property=\"og:image:height\" content=\"797\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Miguel Guti\u00e9rrez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Miguel Guti\u00e9rrez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/\"},\"author\":{\"name\":\"Miguel Guti\u00e9rrez\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#\\\/schema\\\/person\\\/7d19b1faaeac5b8ab56fbdb8f46fc85e\"},\"headline\":\"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA\",\"datePublished\":\"2026-06-22T13:22:34+00:00\",\"dateModified\":\"2026-06-22T13:22:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/\"},\"wordCount\":304,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Portada-Wordpress-Molefy.png\",\"keywords\":[\"AP-2\",\"CSIC\",\"ELA\",\"esclerosis lateral amiotr\u00f3fica\",\"Fase cl\u00ednica\",\"Investigaci\u00f3n\",\"Molefy Pharma\",\"TDP-43\"],\"articleSection\":[\"Investigaci\u00f3n\",\"Reportajes\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/\",\"name\":\"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA - INFO I+D\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Portada-Wordpress-Molefy.png\",\"datePublished\":\"2026-06-22T13:22:34+00:00\",\"dateModified\":\"2026-06-22T13:22:35+00:00\",\"description\":\"La mol\u00e9cula AP-2 podr\u00eda curar la ELA. Este hallazgo es fruto de la investigaci\u00f3n del CSIC y de Molefy Pharma en relaci\u00f3n a la prote\u00edna TDP-43\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/#primaryimage\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Portada-Wordpress-Molefy.png\",\"contentUrl\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/Portada-Wordpress-Molefy.png\",\"width\":1421,\"height\":797},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/2026\\\/06\\\/22\\\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/infoimasd.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#website\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/\",\"name\":\"infoimasd.com\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/infoimasd.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#organization\",\"name\":\"INFO I+D\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Logo-INFO-ID-RELIEVE-150-X-150.png\",\"contentUrl\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Logo-INFO-ID-RELIEVE-150-X-150.png\",\"width\":1254,\"height\":1254,\"caption\":\"INFO I+D\"},\"image\":{\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/#\\\/schema\\\/person\\\/7d19b1faaeac5b8ab56fbdb8f46fc85e\",\"name\":\"Miguel Guti\u00e9rrez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/litespeed\\\/avatar\\\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860\",\"url\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/litespeed\\\/avatar\\\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860\",\"contentUrl\":\"https:\\\/\\\/infoimasd.com\\\/wp-content\\\/litespeed\\\/avatar\\\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860\",\"caption\":\"Miguel Guti\u00e9rrez\"},\"description\":\"Director de INFO I+D\",\"sameAs\":[\"https:\\\/\\\/infoimasd.com\\\/\"],\"url\":\"https:\\\/\\\/infoimasd.com\\\/index.php\\\/author\\\/admin8536\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA - INFO I+D","description":"La mol\u00e9cula AP-2 podr\u00eda curar la ELA. Este hallazgo es fruto de la investigaci\u00f3n del CSIC y de Molefy Pharma en relaci\u00f3n a la prote\u00edna TDP-43","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/","og_locale":"es_ES","og_type":"article","og_title":"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA - INFO I+D","og_description":"La mol\u00e9cula AP-2 podr\u00eda curar la ELA. Este hallazgo es fruto de la investigaci\u00f3n del CSIC y de Molefy Pharma en relaci\u00f3n a la prote\u00edna TDP-43","og_url":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/","og_site_name":"INFO I+D","article_published_time":"2026-06-22T13:22:34+00:00","article_modified_time":"2026-06-22T13:22:35+00:00","og_image":[{"width":1421,"height":797,"url":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/06\/Portada-Wordpress-Molefy.png","type":"image\/png"}],"author":"Miguel Guti\u00e9rrez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Miguel Guti\u00e9rrez","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/#article","isPartOf":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/"},"author":{"name":"Miguel Guti\u00e9rrez","@id":"https:\/\/infoimasd.com\/#\/schema\/person\/7d19b1faaeac5b8ab56fbdb8f46fc85e"},"headline":"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA","datePublished":"2026-06-22T13:22:34+00:00","dateModified":"2026-06-22T13:22:35+00:00","mainEntityOfPage":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/"},"wordCount":304,"commentCount":0,"publisher":{"@id":"https:\/\/infoimasd.com\/#organization"},"image":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/#primaryimage"},"thumbnailUrl":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/06\/Portada-Wordpress-Molefy.png","keywords":["AP-2","CSIC","ELA","esclerosis lateral amiotr\u00f3fica","Fase cl\u00ednica","Investigaci\u00f3n","Molefy Pharma","TDP-43"],"articleSection":["Investigaci\u00f3n","Reportajes"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/","url":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/","name":"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA - INFO I+D","isPartOf":{"@id":"https:\/\/infoimasd.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/#primaryimage"},"image":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/#primaryimage"},"thumbnailUrl":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/06\/Portada-Wordpress-Molefy.png","datePublished":"2026-06-22T13:22:34+00:00","dateModified":"2026-06-22T13:22:35+00:00","description":"La mol\u00e9cula AP-2 podr\u00eda curar la ELA. Este hallazgo es fruto de la investigaci\u00f3n del CSIC y de Molefy Pharma en relaci\u00f3n a la prote\u00edna TDP-43","breadcrumb":{"@id":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/#primaryimage","url":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/06\/Portada-Wordpress-Molefy.png","contentUrl":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/06\/Portada-Wordpress-Molefy.png","width":1421,"height":797},{"@type":"BreadcrumbList","@id":"https:\/\/infoimasd.com\/index.php\/2026\/06\/22\/ap-2-la-prometedora-molecula-candidata-de-molefy-pharma-para-frenar-la-ela\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infoimasd.com\/"},{"@type":"ListItem","position":2,"name":"AP-2, la prometedora mol\u00e9cula candidata de Molefy Pharma para frenar la ELA"}]},{"@type":"WebSite","@id":"https:\/\/infoimasd.com\/#website","url":"https:\/\/infoimasd.com\/","name":"infoimasd.com","description":"","publisher":{"@id":"https:\/\/infoimasd.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infoimasd.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/infoimasd.com\/#organization","name":"INFO I+D","url":"https:\/\/infoimasd.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/infoimasd.com\/#\/schema\/logo\/image\/","url":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/05\/Logo-INFO-ID-RELIEVE-150-X-150.png","contentUrl":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/05\/Logo-INFO-ID-RELIEVE-150-X-150.png","width":1254,"height":1254,"caption":"INFO I+D"},"image":{"@id":"https:\/\/infoimasd.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infoimasd.com\/#\/schema\/person\/7d19b1faaeac5b8ab56fbdb8f46fc85e","name":"Miguel Guti\u00e9rrez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/infoimasd.com\/wp-content\/litespeed\/avatar\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860","url":"https:\/\/infoimasd.com\/wp-content\/litespeed\/avatar\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860","contentUrl":"https:\/\/infoimasd.com\/wp-content\/litespeed\/avatar\/8bbe81d383fcd5d10975c32a324d8b3d.jpg?ver=1790012860","caption":"Miguel Guti\u00e9rrez"},"description":"Director de INFO I+D","sameAs":["https:\/\/infoimasd.com\/"],"url":"https:\/\/infoimasd.com\/index.php\/author\/admin8536\/"}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/infoimasd.com\/wp-content\/uploads\/2026\/06\/Portada-Wordpress-Molefy.png","_links":{"self":[{"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/posts\/797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/comments?post=797"}],"version-history":[{"count":3,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/posts\/797\/revisions"}],"predecessor-version":[{"id":801,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/posts\/797\/revisions\/801"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/media\/798"}],"wp:attachment":[{"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/media?parent=797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/categories?post=797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infoimasd.com\/index.php\/wp-json\/wp\/v2\/tags?post=797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}